Skip to main content

Table 1 Summary of the cytogenetic findings in the seven samples of the patient

From: Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3)

Date Cytogenetic Findings Bone Marrow (BM) Infiltration, Therapy
27.05.2010 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[9]/46,XX[11].
nuc ish(ATM,TP53)×2[204],(D12Z1x3,D13S319x1,LAMP1×2)[158/230],(5’IGHx3,3’IGH×2)(5’IGH sep 3’IGHx1)[167/216]
80% BM infiltration, fludarabine resistance, thrombopenia, therapy switch to rituximab and bendamustine
21.03.2011 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[7].ish der(12)t(12;14)(q23.2;q32.3)x2(5’IGH+).
nuc ish(D12Z1x3,D13S319x1,LAMP1x2)[91/212], (5’IGHx3,3’IGHx2)(5’IGH sep 3’IGHx1)[91/223]
Thrombocytopenia, 40% BM infiltration
24.10.2011 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[17]/46,XX[5] Rituximab and bendamustine
14.03.2012 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[19]/46,XX[1] 95% BM infiltration
11.03.2013 45~47,XX,del(3)(p21),t(12;14)(q23.2;q32.3),+der(12)t(12;14),-13,add(17)(p11.2)[cp8]/46,XX[3].
nuc ish(ATMx2,TP53x1)[121/169],(D12Z3x3,D13S319x0,LAMP1x1)[146/217]/
(D12Z3x3,D13S319x1,LAMP1x1)[17/217]
85% BM infiltration, progression despite therapy with Ibrutinib, lymphadenopathy
03.09.2013 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[5]/46,idem,del(3)(p21),-13,add(17)(p11.2)[3]/46,XX[3] 80% BM infiltration, Alemtuzumab
09.01.2014 47,XX,t(12;14)(q23.2;q32.3),+der(12)t(12;14)[7]/46,idem,del(3)(p21),-13,add(17)(p11.2)[2]/46,XX[6] 96% BM infiltration, sample for expression microarray received
  1. Clinical findings and therapy at the same time points are also stated